Ocrelizumab in the treatment of multiple sclerosis: a literature review
DOI:
https://doi.org/10.52692/1857-0011.2024.3-80.07Keywords:
multiple sclerosis, ocrelizumab, efficacy, quality of life, disease-modifying therapiesAbstract
Ocrelizumab, a humanized monoclonal antibody that targets CD20-positive B cells, has significantly advanced the treatment of multiple sclerosis (MS). Approved for both relapsing-remitting MS and primary progressive MS, it represents a novel approach in MS therapy. Since the end of 2023, Republic of Moldova has incorporated ocrelizumab into its national treatment guidelines, providing access to this innovative therapy for its population. This review provides a detailed analysis of ocrelizumab’s mechanism of action, clinical efficacy, safety profile, and long-term impact based on data from clinical trials and real-world studies. Additionally, the review explores ocrelizumab’s comparison with other disease-modifying therapies, its role in patient quality of life, and the future direction of MS treatment.
References
Thompson, A. J., Barkhof, F., Hohlfeld, R., & Kappos, L. (2018). MS management: Current strategies and future directions. Lancet Neurology, 17(2), 162-173. https://doi.org/10.1016/S0140-6736(18)30481-1
Lassmann, H., van Horssen, J., & Steinman, L. (2018). Multiple sclerosis pathology: Lessons from animal models. Current Opinion in Neurology, 31(3), 255-264. https://doi.org/10.1101/cshperspect.a028936
Filippi, M., Bar-Or, A., & Piehl, F. (2018). Multiple sclerosis. Lancet Neurology, 17(1), 162-173. https://doi.org/10.1038/s41572-018-0041-4
Bar-Or, A., Coyle, P. K., & Ghezzi, A. (2020). Ocrelizumab: Clinical outcomes and future directions. Lancet Neurology, 19(8), 573-588. https://doi.org/10.1016/S1474-4422(20)30162-0
Franciotta, D., Ristori, G., & Borsellino, G. (2018). B cells and the CNS: The impact on MS. Journal of Neuroimmunology, 312(1-2), 74-79. https://doi.org/10.1016/j.jneuro-im.2017.09.004
Hauser, S. L., Bar-Or, A., & Comi, G. (2020). Efficacy and safety of ocrelizumab in RRMS. Lancet, 395(10238), 1698-1707. https://doi.org/10.1016/S0140-6736(20)30676-0
Hauser, S. L., Panitch, H. S., & Birnbaum, G. (2017). Ocrelizumab in RRMS: OPERA I and II results. New England Journal of Medicine, 376(3), 221-234. https://doi.org/10.1056/NEJMoa1607768
Montalban, X., Hauser, S. L., & Kappos, L. (2017). Ocrelizumab in PPMS: ORATORIO trial results. New England Jo- urnal of Medicine, 376(3), 209-220. https://doi.org/10.1056/NEJMoa1606468
Kappos, L., Bar-Or, A., & Gajofatto, A. (2021). Longterm outcomes in MS: Ocrelizumab extension data. Multiple Sclerosis Journal, 27(4), 543-554. https://doi.org/10.1177/1352458520909023
Sormani, M. P., De Rossi, N., & Salvetti, M. (2021). Real-world effectiveness of ocrelizumab: European data. Journal of Neurology, 268(8), 2858-2871. https://doi.org/10.1007/s00415-021-10348-5
Green, A., & Hviid, A. (2019). Safety of long-term ocrelizumab use in MS. Journal of Neuroimmunology, 326, 38-45. https://doi.org/10.1016/j.jneuroim.2018.09.020
Green, A., Bar-Or, A., & Hviid, A. (2020). Ocrelizumab vs. rituximab in MS. Multiple Sclerosis Journal, 26(2), 164-175.
https://doi.org/10.1177/1352458518815873
Leist, T. P., & von Wegner, F. (2020). Off-label use of rituximab in MS: A clinical overview. Neurology, 94(4), 403-411.
https://doi.org/10.1212/WNL.0000000000000123
Lubetzki, C., & Roussel, B. (2020). Combination therapies in MS: Prospects with ocrelizumab. Nature Reviews Drug Discovery, 19(8), 578-596. https://doi.org/10.1038/s41573-020-00071-3
Vermersch, P., & Li, D. K. B. (2021). Quality of life improvements with ocrelizumab: Patient-reported outcomes. Multiple Sclerosis and Related Disorders, 51, 102875. https://doi.org/10.1016/j.msard.2021.102875.
Downloads
Published
License
Copyright (c) 2025 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
